Nouvelle déclaration d'incident
No de la demande: 2009-4695
Numéro de référence du titulaire d'homologation: Prosar 1-19893006
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: IOWA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Non-specific Flea/Tick Powder for Cats (Tetrachlorvinphos)
Poudre
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Cat / Chat
Domestic Longhair
1
Homme
1.5
16
lbs
Cutanée
Unknown / Inconnu
Unknown / Inconnu
Système
Persisted until death
Oui
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
1-19893006: A reporter (cat owner) called on 09/10/2009 to report the exposure of her 3 cats to a flea and tick powder containing the active ingredient Tetrachlorvinphos. According to the reporter, the product was applied to her 3 cats on 09/09/2009. Cat #1 (1st Subform III) developed lethargy, an abnormal gait, anorexia, and stopped drinking later on the day of product application. All 3 cats were bathed with a non-medicated shampoo on 09/10/2009. The other cats remained asymptomatic. Cat #1 was taken to a veterinarian and received a steroid injection and fluid therapy. The reporter was advised that the product contains a cholinesterase inhibitor. Adverse reactions to the product or overdoses may result in signs such as CNS depression, ataxia, increased salivation, tearing of the eyes, excessive urination, vomiting, and diarrhea. A recommendation was made to have the veterinarian conduct cholinesterase testing to determine whether the signs are product-related. The initial reporter's significant other called later on 09/10/2009 to report that Cat #1 was brought home from the clinic and is limp/not able to move and struggling to breathe. The reporter was advised of the active ingredient, and potential signs of overdose/reaction were discussed. The reporter was also advised that treatment includes symptomatic and supportive care and possibly atropine or 2-PAM (the reversal agent). A recommendation was made to have Cat #1 evaluated by an emergency clinic veterinarian for appropriate overnight care. Cholinesterase testing was also discussed. The reporter called back on 09/10/2009 and stated that Cat #1 had died. Necropsy was recommended to try and determine the cause of death. No further information was obtained.
Mort